Citations

Clear

634 citation(s) found for "Hall, A".

Identifying predictive biomarkers for metastatic progression in stage I and II clear cell renal cell carcinoma.
Murphy, Neal , Shih, Andrew , Kozel, Zachary , Shah, Paras , Yaskiv, Oksana, Khalili, Houman , Liew, Anthony, Kavoussi, Louis R., Hall, Simon J. , Vira, Manish , Lee, Annette , Zhu, Xinhua , Khalili, Houman

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 37 | Issue: 7_suppl | Pages: 631-631

10.1200/jco.2019.37.7_suppl.631 Get It

631 Background: For most clear cell renal cell carcinoma (ccRCC) patients with early stage disease, surgical resection offers definitive cure. However, for the small percentage of tumors that metastasize, analyzing gene expression profiles from the primary site at the time of nephrectomy can serve as a model to understand the molecular aberrations behind a metastatic phenotype. Differences in gene expression profiles between patients with Stage I and II ccRCC who experience metastasis versus patients who maintain cure after surgery may help elucidate significant molecular targets and stratify patients at higher risk for metastasis. Methods: Nineteen Stage I and twenty Stage II ccRCC tumors preserved in FFPE blocks after nephrectomy were included in this study. Patients were matched for age, gender, tumor size and grade. In both stages, approximately half the patients that experienced metastasis within 5 years of surgery were part of the experimental group, whereas the control group had > 5 years of follow-up without evidence of disease. Extracted RNA for Stage I patients was sequenced using Illumina TruSeq RNA Access Library. Gene counts were assessed by ht-seq counts and differential expression using DESeq2. Significant genes found were validated in the Stage II group using RT-qPCR. Results: In the Stage I experimental group, statistically significant upregulation of several genes associated with unfavorable prognosis in RCC were found: COL1A1, NUMBL, and STEAP3. Random forest classification accurately separated Stage I control versus experimental patients based on expression of COL1A1. Affected genes were consistent with molecular changes seen in TCGA analysis. In the Stage II group, a double-blinded analysis correctly identified the clinical outcome for the majority of the patients using qPCR expression of COL1A1, NUMBL, and STEAP3. Conclusions: Differences in gene expression profiles harbored in the primary site of early stage ccRCC may be employed to predict patients at high risk for developing metastasis. Validating these findings in a larger study carries the potential to better understand mechanisms of metastasis and identify an at risk cohort of patients with early stage disease.
The use of patient-derived xenograft models for prioritizing therapeutic targets.
Topp, Monique, Hadley, Alison , Heong, Valerie , Harrell, Maria I., McNally, Orla , Lodhia, Kunal A., Study, Australian Ovarian Cancer, Scott, Clare L. , Hadley, Alison Maree, Fox, Stephen B. , Haluska, Paul , Bowtell, David D.L. , Swisher, Elizabeth M. , Wakefield, Matthew J. , Study, Australian Ovarian Cancer

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 5579-5579

10.1200/jco.2015.33.15_suppl.5579 Get It

Clinical evaluation of germline polymorphisms (SNPs) associated with capecitabine (C) toxicity (tox) in metastatic breast cancer (MBC).
O’Donnell, Peter H. , Nurhussein-Patterson, Ashley, Huo, Dezheng , Morrow, Phuong K. , Storniolo, Anna Maria , Forero‐Torres, Andres , Poznak, Catherine Van , Merkel, Douglas E., Rosner, Gary L. , Ratain, Mark J. , Dolan, M. Eileen , Nanda, Rita , Trubetskoy, Vassily Vladimirovich , Hall, Julianne P. , Fleming, Gini F. , Ingle, James N. , Mayer, Ingrid A. , Olopade, Olufunmilayo I. , Cox, Nancy J.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 1049-1049

10.1200/jco.2015.33.15_suppl.1049 Get It

AIDS-Related Kaposi Sarcoma, Version 2.2019
Suneja, Gita , Ambinder, Richard F. , Ard, Kevin L. , Baiocchi, Robert A. , Cohen, Adam K. , Crysler, Oxana , Gupta, Neel K. , Gustafson, Chelsea, Hall, Andre, Johung, Kimberly L. , LaCasce, Ann S. , Lin, Chi , Menon, Manoj , Morgan, David , Nathwani, Nitya , Ratner, Lee , Rizza, Stacey A. , Sanchez, Julian , Taylor, Jeff , Tomlinson, Benjamin , Wang, Chia-Ching J., Dwyer, Mary A., CGC, Freedman-Cass, Deborah A., Rizza, Stacey , Ratner, Lee , Reid, Erin G , Barta, Stefan K , Carchman, Evie H. , Klopp, Ann H. , Mehta, Amitkumar , Noy, Ariela , Rudek, Michelle A. , Yendamuri, Sai S , CGC, Freedman-Cass, Deborah A., Ambinder, Richard F

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 20, 2019 | Volume: 17 | Issue: 2 | Pages: 171-189

10.6004/jnccn.2019.0008 | PMID 30787130 Get It

As treatment of HIV has improved, people living with HIV (PLWH) have experienced a decreased risk of AIDS and AIDS-defining cancers (non-Hodgkin’s lymphoma, Kaposi sarcoma, and cervical cancer), but the risk of Kaposi sarcoma in PLWH is still elevated about 500-fold compared with the general population in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AIDS-Related Kaposi Sarcoma provide diagnosis, treatment, and surveillance recommendations for PLWH who develop limited cutaneous Kaposi sarcoma and for those with advanced cutaneous, oral, visceral, or nodal disease.
A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)
Mossé, Yaël P. , Fox, Elizabeth , Hall, David , Safgren, Stephanie L. , Carol, Hernán, Lock, Richard B. , Houghton, Peter J. , Smith, Malcolm A. , Barkauskas, Donald A. , Krailo, Mark , Voss, Stephan D. , Blaney, Susan M. , Weigel, Brenda J. , Teachey, David T. , Teachey, David T , Reid, Joel M. , Smith, Malcolm A , Berg, Stacey L , Safgren, Stephanie L , Berg, Stacey L.

Mayo Clinic

Clinical Cancer Research | February 18, 2019 | Volume: 25 | Issue: 11 | Pages: 3229-3238

10.1158/1078-0432.ccr-18-2675 | PMID 30777875 Get It

Abstract Purpose: Aurora A kinase (AAK) plays an integral role in mitotic entry, DNA damage checkpoint recovery, and centrosome and spindle maturation. Alisertib (MLN8237) is a potent and selective AAK inhibitor. In pediatric preclinical models, antitumor activity was observed in neuroblastoma, acute lymphoblastic leukemia, and sarcoma xenografts. We conducted a phase 2 trial of alisertib in pediatric patients with refractory or recurrent solid tumors or acute leukemias (NCT01154816). Patients and Methods: Alisertib (80 mg/m2/dose) was administered orally, daily for 7 days every 21 days. Pharmacogenomic (PG) evaluation for polymorphisms in the AURK gene and drug metabolizing enzymes (UGT1A1*28), and plasma pharmacokinetic studies (PK) were performed. Using a 2-stage design, patients were enrolled to 12 disease strata (10 solid tumor and 2 acute leukemia). Response was assessed after cycle 1, then every other cycle. Results: A total of 139 children and adolescents (median age, 10 years) were enrolled, 137 were evaluable for response. Five objective responses were observed (2 complete responses and 3 partial responses). The most frequent toxicity was myelosuppression. The median alisertib trough concentration on day 4 was 1.3 μmol/L, exceeding the 1 μmol/L target trough concentration in 67% of patients. No correlations between PG or PK and toxicity were observed. Conclusions: Despite alisertib activity in pediatric xenograft models and cogent pharmacokinetic-pharmacodynamic relationships in preclinical models and adults, the objective response rate in children and adolescents receiving single-agent alisertib was less than 5%.
Gene-specific features (MLH1, MSH2, MSH6, PMS2) of mismatch repair (MMR) protein expression and somatic mutations (muts), microsatellite instability (MSI) and tumor mutational burden (TMB) in MSI-H and MMR-mutated tumor genomic profiles (TGPs).
Hall, Michael J. , Bodor, J. Nicholas , Xiu, Joanne , Goldberg, Richard M. , Worrilow, William M. , Hwang, Jimmy J., Kim, Edward S. , Lenz, Heinz‐Josef , Shields, Anthony F. , Salem, Mohamed E. , Feldman, Rebecca A. , Grothey, Axel , Raghavan, Derek , Marshall, John L , Korn, Wolfgang Michael

Mayo Clinic

Journal of Clinical Oncology | January 29, 2019 | Volume: 37 | Issue: 4_suppl | Pages: 505-505

10.1200/jco.2019.37.4_suppl.505 Get It

505 Background: MSI is a tumor biomarker for immunotherapy efficacy that is closely associated w/deficient MMR, and is also variably associated w/somatic muts of the MMR genes, loss of MMR protein expression by immunohistochemistry (IHC), and high TMB. Germ-line muts (Lynch syndrome/LS) in the 4 MMR genes are recognized to have distinct cancer spectrums/penetrance in LS, yet across all tumors, gene-specific variability in MMR IHC, MMR muts, and TMB is understudied. Methods: Results of TGPs performed by Caris Lifesciences (2015-17) were analyzed in colorectal (CRC), endometrial (EC) and all other cancers/tumors (OT) as: 1) all MSI-H tumors (n = 1057) and 2) all tumors w/ ≥1 mut in an MMR gene (n = 470). A subset of cases had IHC for MMR protein and PD-L1 expression. MSI and TMB were determined by NGS. Results: Characteristics of MSI-H tumors and tumors w/ ≥1 MMR mut are seen in the Table. A single MSH6 mut [F1088fs] in a coding microsatellite represented 31% of all MMR muts detected. F1088fs was found in 58% tumors w/MLH1/PMS2 loss (IHC) but only 25% w/MSH2/MSH6 loss (p < 0.001), was more commonly seen in EC vs CRC/OT (p < 0.001), and was negatively associated w/somatic POLE mut (p = 0.002). Distinct mut signatures in the MMR genes (e.g. GLUàSTOP) were seen in tumors w/POLE muts and DNA repair genes. Conclusions: MSI-H and MMR mutated tumors demonstrate marked gene-specific heterogeneity in IHC patterns, TMBs, and somatic muts that may be relevant to treatment selection, resistance, and response. [Table: see text]
Hall of Fame Article: Minimally Invasive and Regenerative Therapeutics (Adv. Mater. 1/2019)
Ahadian, Samad , Darabi, Mohammad Ali , Lee, Junmin , Ashammakhi, Nureddin A. , Tahchi, Mario El , Suthiwanich, Kasinan , Sheikhi, Amir , Dokmeci, Mehmet R. , Öklü, Rahmi , Khademhosseini, Ali

Mayo Clinic

Advanced Materials | January 3, 2019 | Volume: 31 | Issue: 1 | Pages: No page available

10.1002/adma.201970005 Get It

Kidney Discard Rates in the United States During American Transplant Congress Meetings
Elhamahmi, Dina Abdelwahab, Chaly, Thomas, Wei, Guo , Hall, Isaac E. , Abdelwahab Elhamahmi, Dina, Chaly, Thomas

Mayo Clinic

Transplantation Direct | December 5, 2018 | Volume: 5 | Issue: 1 | Pages: e412

10.1097/txd.0000000000000849 | PMID 30656210 Get It

Background Deceased-donor kidney discard rates vary by region, but it is unknown whether discard rates and transplant outcomes vary during the American Transplant Congress (ATC) each year. Methods Using national registry data, we determined rates of kidney discard, delayed graft function, graft failure, and mortality from December 31, 1999, through December 30, 2015, during ATC dates and compared these rates with those on the same days of the week during the 2 weeks before and after the ATC (non-ATC). We used multivariable regression to determine associations between ATC and these outcomes. Results From 7902 donors (1575 ATC; 6327 non-ATC), 12 588 recipients received kidney transplants (2455 ATC; 10 133 non-ATC), and 2666 kidneys were discarded (582 ATC; 2084 non-ATC). Kidneys were more often discarded during ATC (19% vs 17%, P = 0.006; adjusted odds ratio, 1.21; 95% confidence interval, 1.05-1.40). There were no significant differences in donor, transplant, or recipient characteristics by ATC/non-ATC dates or by ATC/non-ATC transplant dates for delayed graft function, graft failure, or mortality. Conclusions On the basis of a 21% increased odds of discard, the ATC itself may result in 5 additional kidney discards during this important conference every year, which suggests the need for innovative staffing or other logistic solutions during these planned meetings.
The phosphorylation status of PIP5K1C at serine 448 can be predictive for invasive ductal carcinoma of the breast
Durand, Nisha , Borgés, Sahra, Hall, Tavia, Bastea, Ligia I. , Döppler, Heike, Edenfield, Brandy , Thompson, E. Aubrey , Geiger, Xochiquetzal J., Störz, Peter , Bastea, Ligia, Edenfield, Brandy H, Geiger, Xochiquetzal, Bastea, Ligia

Mayo Clinic

Oncotarget | November 20, 2018 | Volume: 9 | Issue: 91 | Pages: 36358-36370

10.18632/oncotarget.26357 | PMID 30555634 Get It